华润啤酒(00291.HK)全资附属出资1.5亿人币组有限合夥企业
华润啤酒(00291.HK)公布,於今日(26日),全资附属公司华润雪花啤酒投资与横琴润创、深圳博慧及飞宏筑信就成立润慧投资(深圳)有限合夥企业订立协议。
合夥企业的全体合夥人认缴出资额5亿元人民币(下同)。其中,华润雪花啤酒投资、横琴润创、深圳博慧及飞宏筑信分别出资1.5亿元、5,000万元、10万元及2.999亿元。合夥企业的存续期限为7年。
合夥企业主要投资的底层资产为华润雪花啤酒投资的低效资产,包括但不限於因其产能调整停产的工厂的土地使用权及/或土地上的建筑物和设施;及/或风险控制委员会认可的华润雪花啤酒投资的其他低效资产。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.